This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Ovarian Carcinoma
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This study will evaluate NanoPac® administered intraperitoneally (IP) immediately post-cytoreductive surgery, followed by standard of care (SOC) intravenous (IV) chemotherapy, in women with ovarian cancer. The study will compare IP NanoPac® (plus IV chemotherapy) with SOC IV chemotherapy alone.

Provided treatments

  • Drug: NanoPac® 100 mg/m2
  • Drug: NanoPac® 200 mg/m2
  • Drug: NanoPac® 300 mg/m2
  • Drug: NanoPac® 400 mg/m2
  • Drug: Standard of Care Intravenous Chemotherapy
Tris trial is registered with FDA with number: NCT03029585. The sponsor of the trial is NanOlogy, LLC and it is looking for 61 volunteers for the current phase.
Official trial title:
Phase II Study of Four Dose Levels of Intraperitoneal NanoPac® Plus IV Carboplatin and Paclitaxel in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery